NASDAQ
Gyre Therapeutics, Inc. (GYRE)
♥ 509 Thanks from members
Gyre Therapeutics, Inc. (GYRE) reflects mixed sentiment with strong underlying fundamentals but significant liquidity and valuation headwinds, highlighted by a wider Q2 2026 net loss, concentrated insider ownership, and pledged share structures.